---
reference_id: "DOI:10.1085/jgp.202313471"
title: "<i>Tirasemtiv</i> enhances submaximal muscle tension in an <i>Acta1</i>:p.Asp286Gly mouse model of nemaline myopathy"
authors:
- Ricardo A. Galli
- Tamara C. Borsboom
- Charlotte Gineste
- Lorenza Brocca
- Maira Rossi
- Darren T. Hwee
- Fady I. Malik
- Roberto Bottinelli
- Julien Gondin
- Maria-Antonietta Pellegrino
- Josine M. de Winter
- Coen A.C. Ottenheijm
journal: Journal of General Physiology
year: '2024'
doi: 10.1085/jgp.202313471
content_type: abstract_only
---

# <i>Tirasemtiv</i> enhances submaximal muscle tension in an <i>Acta1</i>:p.Asp286Gly mouse model of nemaline myopathy
**Authors:** Ricardo A. Galli, Tamara C. Borsboom, Charlotte Gineste, Lorenza Brocca, Maira Rossi, Darren T. Hwee, Fady I. Malik, Roberto Bottinelli, Julien Gondin, Maria-Antonietta Pellegrino, Josine M. de Winter, Coen A.C. Ottenheijm
**Journal:** Journal of General Physiology (2024)
**DOI:** [10.1085/jgp.202313471](https://doi.org/10.1085/jgp.202313471)

## Content

Nemaline myopathies are the most common form of congenital myopathies. Variants in ACTA1 (NEM3) comprise 15â€“25% of all nemaline myopathy cases. Patients harboring variants in ACTA1 present with a heterogeneous disease course characterized by stable or progressive muscle weakness and, in severe cases, respiratory failure and death. To date, no specific treatments are available. Since NEM3 is an actin-based thin filament disease, we tested the ability of tirasemtiv, a fast skeletal muscle troponin activator, to improve skeletal muscle function in a mouse model of NEM3, harboring the patient-based p.Asp286Gly variant in Acta1. Acute and long-term tirasemtiv treatment significantly increased muscle contractile capacity at submaximal stimulation frequencies in both fast-twitch extensor digitorum longus and gastrocnemius muscle, and intermediate-twitch diaphragm muscle in vitro and in vivo. Additionally, long-term tirasemtiv treatment in NEM3 mice resulted in a decreased respiratory rate with preserved minute volume, suggesting more efficient respiration. Altogether, our data support the therapeutic potential of fast skeletal muscle troponin activators in alleviating skeletal muscle weakness in a mouse model of NEM3 caused by the Acta1:p.Asp286Gly variant.